Transforming cancer treatment and advancing new therapies through empowered science.
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to...
NASDAQ | SGEN (Common Stock)
10/09/15 4:00 p.m. ET
Minimum 20 minute delay
Latest Investor Information
Press ReleasesSeattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2015 Financial Results on October 29, 2015 10/08/15Seattle Genetics Announces Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Second-line Hodgkin Lymphoma 10/07/15
EventsThird Quarter 2015 Financial Results Conference Call10/29/15 4:30 p.m. ETView eventSecond Quarter 2015 Financial Results Conference Call07/30/15 4:30 p.m. ETView event
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|